Measurements of hypoxia using pimonidazole and polarographic oxygen-sensitive electrodes in human cervix carcinomas

被引:124
作者
Nordsmark, M [1 ]
Loncaster, J
Aquino-Parsons, C
Chou, SC
Ladekarl, M
Havsteen, H
Lindegaard, JC
Davidson, SE
Varia, M
West, C
Hunter, R
Overgaard, J
Raleigh, JA
机构
[1] Aarhus Univ Hosp, Dept Expt Clin Oncol, DK-8000 Aarhus, Denmark
[2] Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark
[3] Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England
[4] BC Can Agcy, Dept Radiat Oncol, Vancouver, BC, Canada
[5] UNC CH Sch Med, Dept Radiat Oncol, Chapel Hill, NC USA
关键词
tumour oxygenation; hypoxia marker; pimonidazole; uterine cervix carcinoma;
D O I
10.1016/S0167-8140(03)00010-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and put-pose: The measurement of tumour oxygenation using Eppendorf oxygen-sensitive needle electrodes can provide prognostic information but the method is limited to accessible tumours that are suitable for electrode insertion. In this paper the aim was to study the relationship between such physiological measurements of tumour hypoxia and the labelling of tumours with the hypoxia-specific marker pimonidazole. Materials and methods: Assessment of tumour oxygen partial pressure (pO(2)) using an Eppendorf pO(2) histograph and immunohistochemical pimonidazole labelling was carried out in 86 patients with primary cervix carcinomas. Pimonidazole was given as a single injection (0.5 g/m(2) i.v.) and 10-24 h later pO(2) measurements were made and biopsies taken. Tumour oxygenation status was evaluated as the median tumour pO(2) and the fraction of pO(2) values less than or equal to 10 mmHg (HPIO), less than or equal to 5 mmHg (HP5) and less than or equal to 2.5 mmHg (HP2.5). Hypoxia was detected by immunohistochemistry using monoclonal antibodies directed against reductively activated pimonidazole. Pimonidazole binding was scored using a light microscope. Each tumour was evaluated by the relative area pimonidazole at highest score and the accumulated area of pimonidazole labelling from score 1 to 4. Necrosis was measured in HE stained sections. Results and conclusions: The degree of hypoxia assessed by either pimonidazole binding or invasive electrode measurements varied significantly between tumours. There was a trend that the most hypoxic tumours measured by oxygen electrodes had the highest score of necrosis, and no or little pimonidazole binding. However, this observation was not consistent and there was no correlation between pimonidazole staining expressed in this way and oxygen electrode measurements of hypoxia. (C) 2003 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:35 / 44
页数:10
相关论文
共 33 条
[1]   Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state [J].
Arteel, GE ;
Thurman, RG ;
Raleigh, JA .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1998, 253 (03) :743-750
[2]   EVIDENCE THAT HYPOXIA MARKERS DETECT OXYGEN GRADIENTS IN LIVER - PIMONIDAZOLE AND RETROGRADE PERFUSION OF RAT-LIVER [J].
ARTEEL, GE ;
THURMAN, RG ;
YATES, JM ;
RALEIGH, JA .
BRITISH JOURNAL OF CANCER, 1995, 72 (04) :889-895
[3]   Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime [J].
Azuma, C ;
Raleigh, JA ;
Thrall, DE .
RADIATION RESEARCH, 1997, 148 (01) :35-42
[4]  
Begg AC, 2001, ACTA ONCOL, V40, P924
[5]  
BENTZEN L, UNPUB RADIOTHER ONCO
[6]  
Brizel DM, 1996, CANCER RES, V56, P941
[7]   Vascular architecture and microenvironmental parameters in human squamous cell carcinoma xenografts, effects of carbogen and nicotinamide [J].
Bussink, J ;
Kaanders, JHAM ;
Rijken, PFJW ;
Peters, JPW ;
Hodgkiss, RJ ;
Marres, HAM ;
van der Kogel, AJ .
RADIOTHERAPY AND ONCOLOGY, 1999, 50 (02) :173-184
[8]   Inducible repair and the two forms of tumour hypoxia - Time for a paradigm shift [J].
Denekamp, J ;
Dasu, A .
ACTA ONCOLOGICA, 1999, 38 (07) :903-918
[9]  
Evans SM, 2000, CANCER RES, V60, P2018
[10]   Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer [J].
Fyles, A ;
Milosevic, M ;
Hedley, D ;
Pintilie, M ;
Levin, W ;
Manchul, L ;
Hill, RP .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (03) :680-687